0001193125-23-202349.txt : 20230803 0001193125-23-202349.hdr.sgml : 20230803 20230803084502 ACCESSION NUMBER: 0001193125-23-202349 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230803 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230803 DATE AS OF CHANGE: 20230803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sensei Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001829802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39980 FILM NUMBER: 231138270 BUSINESS ADDRESS: STREET 1: 1405 RESEARCH BLVD, SUITE 125 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (240) 243-8000 MAIL ADDRESS: STREET 1: 1405 RESEARCH BLVD, SUITE 125 CITY: ROCKVILLE STATE: MD ZIP: 20850 8-K 1 d518119d8k.htm 8-K 8-K
false 0001829802 0001829802 2023-08-03 2023-08-03 0001829802 us-gaap:CommonStockMember 2023-08-03 2023-08-03 0001829802 us-gaap:SeriesAPreferredStockMember 2023-08-03 2023-08-03

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 3, 2023

 

 

Sensei Biotherapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-39980   83-1863385

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

1405 Research Blvd, Suite 125

Rockville, MD

   20850
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (240) 243-8000

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class

  

Trading

symbol

  

Name of each exchange

on which registered

Common Stock   SNSE   The Nasdaq Stock Market LLC
Series A Preferred Stock Purchase Rights     The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition.

On August 3, 2023, Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
Number

   

Exhibit Description

99.1    Press Release of Sensei Biotherapeutics, Inc., dated August 3, 2023
104    The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

 

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      Sensei Biotherapeutics, Inc.
Date: August 3, 2023      

/s/ Christopher W. Gerry

      Christopher W. Gerry
      General Counsel and Secretary

 

3

EX-99.1 2 d518119dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Phase 1/2 clinical trial enrolling for lead investigational candidate SNS-101, a conditionally active VISTA-

blocking antibody for the treatment of advanced solid tumors

A total of 6 patients in three dosing cohorts enrolled to date, with initiation of combination arm now

planned for Q4 2023

Initial PK and safety data now expected by year-end 2023, and topline efficacy and biomarker data

expected in 2024

Strong balance sheet with cash runway into the second half of 2025

BOSTON, MA – August 3, 2023 – Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended June 30, 2023, and provided recent business updates.

“The second quarter of 2023 was momentous for Sensei as we moved expeditiously from the FDA’s clearance of our SNS-101 trial in April to the enrollment of six patients by the end of July. We’re encouraged by the rapid clinical enrollment activity we’ve observed so far, which suggests that we may be able to accelerate the start of the combination arm of this study,” said John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics. “We’re grateful for the efforts of the clinical investigators, patients, and families without whom this clinical trial would not be possible.”

Highlights and Milestones

SNS-101

Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), which is implicated in numerous cancer indications and whose expression correlates with low survival rates.

Recent updates for SNS-101 include:

 

  •  

An Investigational New Drug (IND) application for SNS-101 was cleared by the U.S. Food and Drug Administration (FDA) in April 2023. The cleared starting dose of 0.3 mg/kg was substantially higher than other anti-VISTA antibodies.

 

  •  

On June 1, 2023, Sensei reported the first patient dosed in the dose escalation portion of the SNS-101 multi-center Phase 1/2 clinical trial. To date, Sensei has enrolled a total of 6 patients, clearing its first patient cohort at 0.3 mg/kg and its second patient cohort at 1.0 mg/kg, and is currently dosing patients in its third cohort at 3.0 mg/kg.

 

  •  

As a result of the pace of enrollment to date, Sensei expects to dose the first patient in combination with Regeneron’s PD-1 inhibitor Libtayo® (cemiplimab) in Q4 2023.

  •  

Sensei now expects to report initial pharmacokinetic (PK) and safety data by year-end 2023, and topline monotherapy data and initial combination data for the Phase 1/2 clinical trial in 2024.

 

  •  

On June 27, 2023, Sensei provided an overview of SNS-101 and its Phase 1/2 clinical trial in a virtual KOL event entitled “A New VISTA for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors.” A link to the event recording can be accessed on the Sensei website. For this event, Sensei welcomed James Gulley, M.D., Ph.D., Co-Director of the Center for Immuno-Oncology, and Clinical Director at the National Cancer Institute (NCI), part of the National Institutes of Health, to provide an overview of today’s immuno-oncology treatment landscape and discuss NCI’s Cooperative Research & Development Agreement (CRADA) with Sensei, which includes ongoing research to further elucidate the role of VISTA in immune checkpoint resistance, research to expand the potential of SNS-101 as a combination therapy beyond anti-PD-1, and NCI serving as a clinical site for the SNS-101 Phase 1/2 clinical trial.

Other TMAb™ Platform Updates

Through its Tumor Microenvironment Activated biologics (TMAb) platform, Sensei is advancing several conditionally active antibody programs, including SNS-102 targeting VSIG4 (V-Set and Immunoglobulin Domain Containing 4), SNS-103 targeting ENTPDase1 (ecto-nucleoside triphosphate diphosphohydrolase-1, also known as CD39) and a recently initiated bispecific antibody program.

Recent updates include:

 

  •  

Sensei has completed lead optimization for its programs SNS-102 (targeting VSIG4) and SNS-103 (targeting CD-39) and is currently characterizing potential lead antibodies for each program. Sensei remains on track to select product candidates for both SNS-102 and SNS-103 in 2023.

 

  •  

Sensei’s early discovery bispecific antibody program has generated an initial set of conditionally active bispecific antibodies that are currently being characterized.

 

  •  

Upon successful candidate selection, Sensei expects to advance one product candidate to IND-enabling studies.

Additional Updates

Robert Schreiber, Ph.D., Professor of Pathology & Immunology and Director of the Center for Human Immunology and Immunotherapy Programs at Washington University, has been appointed Chair of Sensei’s Immuno-Oncology Advisory Board. Dr. Schreiber was largely responsible for defining the concept of cancer immunoediting and his research focuses on elucidating the biochemistry and molecular cell biology of immune responses to developing and established tumors. He is an expert on VISTA, the target of Sensei’s lead program SNS-101, and his laboratory at Washington University in St. Louis, MO has partnered with Sensei to support the continued clinical development of SNS-101.

Second Quarter 2023 Financial Results

Cash Position: Cash, cash equivalents and marketable securities were $78.8 million as of June 30, 2023, as compared to $107.1 million as of December 31, 2022. The decrease is due to cash used to fund operations and $7.8 million relating to shares repurchased within the period. Sensei expects its current cash balance to fund operations into the second half of 2025.

Research and Development (R&D) Expenses: R&D expenses were $4.8 million for the quarter ended June 30, 2023, compared to $6.4 million for the quarter ended June 30, 2022. The decrease in R&D expenses was primarily attributable to lower personnel costs due to the Company’s December 2022 restructuring, lower expense relating to lab supply purchases and lower manufacturing-related expenses, partially offset by increased expense relating to outside research fees and higher expense associated with clinical trials.

General and Administrative (G&A) Expenses: G&A expenses were $5.4 million for the quarter ended June 30, 2023, compared to $4.3 million for the quarter ended June 30, 2022. The increase in G&A expense was primarily attributable to external professional services, including $1.56 million of non-recurring expenses associated with stockholder activism related to our 2023 annual meeting of stockholders, partially offset by lower recruiting expense.

Net Loss: Net loss was $9.4 million for the quarter ended June 30, 2023, compared to $10.5 million for the quarter ended June 30, 2022.

About Sensei Biotherapeutics

Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditional binding monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4), as well as SNS-103, also a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39. For more information, please visit www.senseibio.com, and follow the company on Twitter @SenseiBio and LinkedIn.

Condensed Statements of Operations

(Unaudited, in thousands except share and per share data)

 

     Three Months Ended
June 30,		  
     2023      2022  

Operating expenses:

      

Research and development

    $ 4,784      $ 6,393  

General and administrative

      5,393        4,319  
  

 

 

     

 

 

  

Total operating expenses

      10,177        10,712  
  

 

 

     

 

 

  

Loss from operations

      (10,177 )       (10,712 ) 

Total other income

      791        177  
  

 

 

     

 

 

  

Net loss

      (9,386 )       (10,535 ) 

Net loss per share, basic and diluted

    $ (0.31 )     $ (0.34 ) 
  

 

 

     

 

 

  

Weighted-average common shares outstanding, basic and diluted

      30,507,018        30,701,758  
  

 

 

     

 

 

  

Selected Condensed Balance Sheet Data

(Unaudited, in thousands)

 

     June 30,
2023		      December 31,
2022		  

Cash and cash equivalents

    $ 10,226      $ 17,795  

Marketable securities

      68,614        89,321  

Total assets

      89,580        118,375  

Total liabilities

      10,379        14,968  

Total stockholders’ equity

      79,201        103,407  

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “believe”, “designed to,” “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Sensei’s current beliefs and expectations. These forward-looking statements include expectations regarding the development and potential therapeutic benefits of Sensei’s product candidates, the timing of Sensei’s Phase 1/2 clinical trial of SNS-101, including reporting of data therefrom, the timing of selection of product candidates, and its belief that its existing cash and cash equivalents will be sufficient to fund its operations at least into the second half of 2025. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Sensei’s product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Sensei’s product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical trials, will not be replicated or will not

continue in ongoing or future studies or clinical trials involving Sensei’s product candidates; the risk that Sensei’s product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate; risks associated with Sensei’s dependence on third-party suppliers and manufacturers, including sole source suppliers, over which we may not always have full control; risks regarding the accuracy of our estimates of expenses, capital requirements and needs for additional financing; and other risks and uncertainties that are described in Sensei’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) on or about August 3, 2023 and Sensei’s other Periodic Reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Sensei as of the date of this release, and Sensei assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Michael Biega

Senior Director, Investor Relations

Sensei Biotherapeutics

mbiega@senseibio.com

Media Contact:

Chris Railey

Ten Bridge Communications

chris@tenbridgecommunications.com

EX-101.SCH 3 snse-20230803.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 snse-20230803_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 snse-20230803_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] Series A Preferred Stock [Member] Series A Preferred Stock [Member] EX-101.PRE 6 snse-20230803_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Aug. 03, 2023
Document And Entity Information [Line Items]  
Amendment Flag false
Entity Central Index Key 0001829802
Document Type 8-K
Document Period End Date Aug. 03, 2023
Entity Registrant Name Sensei Biotherapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39980
Entity Tax Identification Number 83-1863385
Entity Address, Address Line One 1405 Research Blvd
Entity Address, Address Line Two Suite 125
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code 240
Local Phone Number 243-8000
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period false
Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Common Stock
Trading Symbol SNSE
Security Exchange Name NASDAQ
Series A Preferred Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Series A Preferred Stock Purchase Rights
Security Exchange Name NASDAQ
XML 8 d518119d8k_htm.xml IDEA: XBRL DOCUMENT 0001829802 2023-08-03 2023-08-03 0001829802 us-gaap:CommonStockMember 2023-08-03 2023-08-03 0001829802 us-gaap:SeriesAPreferredStockMember 2023-08-03 2023-08-03 false 0001829802 8-K 2023-08-03 Sensei Biotherapeutics, Inc. DE 001-39980 83-1863385 1405 Research Blvd Suite 125 Rockville MD 20850 240 243-8000 false false false false Common Stock SNSE NASDAQ Series A Preferred Stock Purchase Rights NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 3 24 1 false 2 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [dq-60546-SecurityExchangeName-TradingSymbol, NoTradingSymbolFlag-Dependency] In submission type 8-K, SecurityExchangeName should have a value if one of TradingSymbol, NoTradingSymbolFlag has a value in context duration_2023-08-03_to_2023-08-03_us-gaap-StatementClassOfStockAxis_us-gaap-SeriesAPreferredStockMember. d518119d8k.htm 80 d518119d8k.htm d518119dex991.htm snse-20230803.xsd snse-20230803_def.xml snse-20230803_lab.xml snse-20230803_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d518119d8k.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 26 }, "contextCount": 3, "dts": { "definitionLink": { "local": [ "snse-20230803_def.xml" ] }, "inline": { "local": [ "d518119d8k.htm" ] }, "labelLink": { "local": [ "snse-20230803_lab.xml" ] }, "presentationLink": { "local": [ "snse-20230803_pre.xml" ] }, "schema": { "local": [ "snse-20230803.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 31, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 2, "nsprefix": "snse", "nsuri": "http://senseibio.com/20230803", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d518119d8k.htm", "contextRef": "duration_2023-08-03_to_2023-08-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d518119d8k.htm", "contextRef": "duration_2023-08-03_to_2023-08-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 2, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "snse_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://senseibio.com/20230803", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "snse_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://senseibio.com/20230803", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://senseibio.com//20230803/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001193125-23-202349-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-202349-xbrl.zip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